journal article
Open Access
Apr 04, 2026
Antimicrobial Drug Prophylaxis for Recurrent Ocular Toxoplasmosis
Abstract
Ocular toxoplasmosis is a relapsing infectious eye disease that carries an increasing risk of vision loss with each reactivation episode. Antimicrobial drug prophylaxis has been used to reduce the rate of recurrence. This review aims to summarize the current literature regarding expert clinician preferences, as well as the effectiveness and safety of prophylaxis. A literature search was conducted using the PubMed platform of the National Library of Medicine of the National Center for Biotechnology Information and relevant pre-specified search terms. Four professional surveys indicated that approximately three-quarters of experts gave antimicrobial drug prophylaxis for recurrent ocular toxoplasmosis, and that trimethoprim-sulfamethoxazole was the most popular approach. Clinical studies of prophylaxis varied in multiple parameters, including drug, dosing and duration, plus time of follow-up. Considering the four studies with at least 50 participants, the rate of recurrence of ocular toxoplasmosis within 5 years was up to 9.1% of patients taking prophylaxis, and treatment-limiting side effects occurred in up to 7.9% of patients. The available literature demonstrates that antimicrobial drug prophylaxis can reduce the recurrence rate of ocular toxoplasmosis; however, further research on drug dosing and duration of treatment is required to assist decision-making in clinical practice.
Topics
No keywords indexed for this article. Browse by subject →
References
30
[1]
Akins, G.K.H., Furtado, J.M., and Smith, J.R. (2024). Diseases caused by and behaviors associated with Toxoplasma gondii infection. Pathogens, 13.
10.3390/pathogens13110968
[2]
Kalogeropoulos "Ocular toxoplasmosis: A review of the current diagnostic and therapeutic approaches" Int. Ophthalmol. (2022) 10.1007/s10792-021-01994-9
[3]
"Quality of life assessment in ocular toxoplasmosis in a Colombian population" Ocul. Immunol. Inflamm. (2011) 10.3109/09273948.2011.582220
[4]
Canamary "Quality-of-life and psychosocial aspects in patients with ocular toxoplasmosis: A clinical study in a tertiary care hospital in Brazil" Ocul. Immunol. Inflamm. (2020) 10.1080/09273948.2019.1612453
[5]
Smith "Pathogenesis of ocular toxoplasmosis" Prog. Retin. Eye Res. (2021) 10.1016/j.preteyeres.2020.100882
[6]
Holland "Ocular toxoplasmosis: A global reassessment. Part I: Epidemiology and course of disease" Am. J. Ophthalmol. (2003) 10.1016/j.ajo.2003.09.040
[7]
Cuevas "Clinical characteristics associated with complications and poor visual outcomes in ocular toxoplasmosis: Analysis of 853 patients" Am. J. Ophthalmol. (2025) 10.1016/j.ajo.2025.02.027
[8]
Yogeswaran "Current practice in the management of ocular toxoplasmosis" Br. J. Ophthalmol. (2023) 10.1136/bjophthalmol-2022-321091
[9]
Silveira "The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis" Am. J. Ophthalmol. (2002) 10.1016/s0002-9394(02)01527-1
[10]
Kim "Interventions for toxoplasma retinochoroiditis: A report by the American Academy of Ophthalmology" Ophthalmology (2013) 10.1016/j.ophtha.2012.07.061
[11]
Morais "Current Practices in Ocular Toxoplasmosis: A survey of Brazilian uveitis specialists" Ocul. Immunol. Inflamm. (2018) 10.1080/09273948.2016.1215471
[12]
Schaeffer "Management of ocular toxoplasmosis in France: Results of a modified Delphi study" J. Fr. Ophtalmol. (2022) 10.1016/j.jfo.2021.11.007
[13]
Garweg "Diagnostics and treatment of ocular toxoplasmosis: Results of a survey" Ophthalmologie (2023)
[14]
Linton "Prophylactic treatment of recurrent attacks of uveitis due to I. toxoplasmosis and 2. streptococci" Trans. Aust. Coll. Ophthalmol. (1969)
[15]
Amato "Recurrent acquired ocular toxoplasmosis associated with Kyrieleis plaques and documented allergy to sulfonamide—A treatment proposal for two rare conditions" Diagn. Microbiol. Infect. Dis. (2024) 10.1016/j.diagmicrobio.2024.116266
[16]
Lira "Trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrences of Toxoplasma gondii retinochoroiditis: Randomized controlled clinical trial" Am. J. Ophthalmol. (2014) 10.1016/j.ajo.2013.12.022
[17]
Cosimo "Trimethoprim-sulfamethoxazole versus placebo in reducing the risk of toxoplasmic retinochoroiditis recurrences: A three-year follow-up" Am. J. Ophthalmol. (2016) 10.1016/j.ajo.2016.08.003
[18]
Grupenmacher "Long-term results of trimethoprim-sulfamethoxazole versus placebo to reduce the risk of recurrent Toxoplasma gondii retinochoroiditis" Am. J. Ophthalmol. (2020) 10.1016/j.ajo.2019.12.025
[19]
Silveira "The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis: 10 years of follow-up" Ocul. Immunol. Inflamm. (2015) 10.3109/09273948.2014.964422
[20]
Borkowski, P.K., Brydak-Godowska, J., Basiak, W., Świtaj, K., Żarnowska-Prymek, H., Olszyńska-Krowicka, M., Kajfasz, P., and Rabczenko, D. (2016). The impact of short-term, intensive antifolate treatment (with pyrimethamine and sulfadoxine) and antibiotics followed by long-term, secondary antifolate prophylaxis on the rate of toxoplasmic retinochoroiditis recurrence. PLoS Negl. Trop. Dis., 10.
10.1371/journal.pntd.0004892
[21]
Borkowski "Adverse reactions in antifolate-treated toxoplasmic retinochoroiditis" Adv. Exp. Med. Biol. (2018) 10.1007/5584_2018_262
[22]
Hébert, M., Bouhout, S., Vadboncoeur, J., and Aubin, M.J. (2022). Recurrent and de novo toxoplasmosis retinochoroiditis following coronavirus disease 2019 infection or vaccination. Vaccines, 10.
10.3390/vaccines10101692
[23]
Kopec "Prophylaxis for ocular toxoplasmosis" Clin. Infect. Dis. (2003) 10.1086/379125
[24]
Matet "Clinical and biological factors associated with recurrences of severe toxoplasmic retinochoroiditis confirmed by aqueous humor analysis" Am. J. Ophthalmol. (2019) 10.1016/j.ajo.2018.11.013
[25]
Saad "Failure of systemic oral doxycycline in preventing ocular toxoplasmic retinochoroiditis in French military personnel" J. R. Army Med. Corps (2018) 10.1136/jramc-2017-000854
[26]
Zamora "Long-term low-dose pyrimethamine use for the prevention of ocular toxoplasmosis recurrences: A cohort study" Ocul. Immunol. Inflamm. (2024) 10.1080/09273948.2024.2321270
[27]
Cavattoni "Diagnosis of Toxoplasma gondii infection after allogeneic stem cell transplant can be difficult and requires intensive scrutiny" Leuk Lymphoma (2010) 10.3109/10428194.2010.494260
[28]
McDermott "Case report: Ocular toxoplasmosis in a WHIM syndrome immunodeficiency patient" F1000Res (2019) 10.12688/f1000research.16825.1
[29]
Webb "Post-prophylaxis toxoplasma chorioretinitis following donor-recipient mismatched liver transplantation" Transpl. Infect. Dis. (2016) 10.1111/tid.12589
[30]
Pradhan "Antibiotics versus no treatment for toxoplasma retinochoroiditis" Cochrane Database Syst. Rev. (2016)
Metrics
0
Citations
30
References
Details
- Published
- Apr 04, 2026
- Vol/Issue
- 15(4)
- Pages
- 388
- License
- View
Authors
Funding
National Health and Medical Research Council
Award: 2025222
Brazilian National Council for Scientific and Technological Development
Award: 306547/2025-2
Cite This Article
Taraneh Keshavarz, João M. Furtado, Justine R. Smith (2026). Antimicrobial Drug Prophylaxis for Recurrent Ocular Toxoplasmosis. Pathogens, 15(4), 388. https://doi.org/10.3390/pathogens15040388
Related
You May Also Like
Bacterial Antibiotic Resistance: The Most Critical Pathogens
Giuseppe Mancuso, Angelina Midiri · 2021
1,144 citations
Acinetobacter baumannii Antibiotic Resistance Mechanisms
Ioannis Kyriakidis, Eleni Vasileiou · 2021
528 citations
From in vitro to in vivo Models of Bacterial Biofilm-Related Infections
David Lebeaux, Ashwini Chauhan · 2013
456 citations
Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks
Hossam M. Ashour, Walid F. Elkhatib · 2020
427 citations
Phenylpropanoid Pathway Engineering: An Emerging Approach towards Plant Defense
Vivek Yadav, Zhongyuan Wang · 2020
423 citations